Literature DB >> 1653070

Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

G Dent1, M A Giembycz, K F Rabe, P J Barnes.   

Abstract

1. The cyclic nucleotide phosphodiesterase (PDE) of guinea-pig eosinophils was partially characterized and the effects of selective inhibitors of PDE isoenzymes upon opsonized zymosan (OZ)-stimulated respiratory burst were studied. 2. PDE activity in eosinophil lysates appeared to be membrane-associated, displayed substrate specificity for adenosine 3':5' cyclic monophosphate (cyclic AMP) versus guanosine 3':5' cyclic monophosphate (cyclic GMP) and was insensitive to cyclic GMP or Ca2+ and calmodulin. 3. The non-selective PDE inhibitor, 3-isobutyl-1-methylxanthine caused a concentration-dependent inhibition of both OZ-stimulated hydrogen peroxide (H2O2) generation and cyclic AMP hydrolysis. The type IV-selective PDE inhibitors, rolipram and denbufylline, also inhibited H2O2 generation and cyclic AMP hydrolysis in a concentration-dependent manner whilst SK&F 94120 and Org 9935 (type III-selective) and zaprinast (type Ia or V-selective) were ineffective. 4. Dibutyryl cyclic AMP, a cell-permeable, non-hydrolysable analogue of cyclic AMP, caused a concentration-dependent inhibition of H2O2 generation stimulated by OZ. Dibutyryl cyclic GMP was ineffective. 5. It is concluded that eosinophil respiratory burst activity induced by OZ can be regulated by intracellular cyclic AMP and that the levels of cyclic AMP are controlled exclusively by a rolipram- and denbufylline-sensitive PDE isoenzyme that resembles a type IV species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653070      PMCID: PMC1908391          DOI: 10.1111/j.1476-5381.1991.tb09790.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  On the evaluation of the constants Vm and KM in enzyme reactions.

Authors:  B H J HOFSTEE
Journal:  Science       Date:  1952-09-26       Impact factor: 47.728

2.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

Review 3.  Selectivity of action can be achieved with compounds acting at second messenger targets.

Authors:  D Corda; A Luini; S Garattini
Journal:  Trends Pharmacol Sci       Date:  1990-12       Impact factor: 14.819

4.  Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.

Authors:  S A Harrison; D H Reifsnyder; B Gallis; G G Cadd; J A Beavo
Journal:  Mol Pharmacol       Date:  1986-05       Impact factor: 4.436

5.  The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.

Authors:  M L Reeves; B K Leigh; P J England
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

6.  The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site.

Authors:  C D Nicholson; S A Jackman; R Wilke
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

7.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

8.  H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors.

Authors:  R K Root; J Metcalf; N Oshino; B Chance
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

9.  Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.

Authors:  A L Harris; M J Connell; E W Ferguson; A M Wallace; R J Gordon; E D Pagani; P J Silver
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

10.  Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.

Authors:  C P Nielson; R E Vestal; R J Sturm; R Heaslip
Journal:  J Allergy Clin Immunol       Date:  1990-11       Impact factor: 10.793

View more
  26 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 2.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

3.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 4.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.

Authors:  M Grous; M Barnette
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

6.  Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.

Authors:  E R Pettipher; J M Labasi; E D Salter; E J Stam; J B Cheng; R J Griffiths
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

7.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors:  H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.